CMP
MRVI icon

Coston McIsaac & Partners’s Maravai LifeSciences MRVI Stock Holding History

Coston McIsaac & Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2
Closed – – 878
2025
Q3 		$0 Hold
2
– – ﹤0.01% 830
2025
Q2 		$0 Buy
+2
New +$4 ﹤0.01% 803
2025
Q1 		– Sell
-2
Closed – – 803
2024
Q4 		$0 Hold
2
– – ﹤0.01% 802
2024
Q3 		$0 Hold
2
– – ﹤0.01% 794
2024
Q2 		$0 Hold
2
– – ﹤0.01% 775
2024
Q1 		$0 Hold
2
– – ﹤0.01% 757
2023
Q4 		$0 Hold
2
– – ﹤0.01% 757
2023
Q3 		$0 Hold
2
– – ﹤0.01% 764
2023
Q2 		$0 Hold
2
– – ﹤0.01% 817
2023
Q1 		$0 Hold
2
– – ﹤0.01% 832
2022
Q4 		$0 Hold
2
– – ﹤0.01% 797
2022
Q3 		$0 Hold
2
– – ﹤0.01% 717
2022
Q2 		$0 Buy
+2
New +$63 ﹤0.01% 497

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coston McIsaac & Partners's MRVI Position: Q4 2025 in Review

Coston McIsaac & Partners sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 2 shares.

Coston McIsaac & Partners first reported a position in MRVI in Q2 2022 and held it in 13 quarters. The position peaked at $0 in Q3 2025. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • Coston McIsaac & Partners reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • Coston McIsaac & Partners sold 2 Maravai LifeSciences shares in Q4 2025.
  • Coston McIsaac & Partners first reported a position in Maravai LifeSciences in Q2 2022 and held it in 13 quarters.
  • Coston McIsaac & Partners's Maravai LifeSciences position peaked at $0 in Q3 2025.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Coston McIsaac & Partners's 13F filing for Q4 2025, filed 3 Feb 2026.